← Back to all trials
Recruiting
NCT07487363
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD
Conditions: Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction
Sex: All
Ages: 40 Years – 75 Years
Healthy volunteers: No
Phase: PHASE1, PHASE2
Enrollment: 80
Sponsor: Hudson Biotech
Location: Peking University Shenzhen Hospital Shenzhen Guangdong
Summary
Phase 1/2 trial evaluating the safety and tolerability of TB-500 (a 17-23 fragment of thymosin beta 4) versus placebo in adults with stable atherosclerotic cardiovascular disease (ASCVD). Exploratory endpoints assess vascular function and inflammation biomarkers
Eligibility Criteria
Inclusion Criteria:
* Age 40-75 years, able to provide written informed consent.
* Documented stable ASCVD (e.g., prior myocardial infarction \>6 months ago, prior coronary revascularization, stable angina with objective evidence of ischemia, or symptomatic peripheral artery disease).
* On stable guideline-directed medical therapy (e.g., statin and antiplatelet therapy unless contraindicated) for at least 8 weeks before screening.
* Resting systolic blood pressure \
Source: ClinicalTrials.gov (NCT07487363). StuddyBuddy aggregates publicly available trial information.
